Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423691 · ClinicalTrials.gov registry record · Phase 1
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
A Phase 1 study of Myelofibrosis, sponsored by Cellenkos.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT05423691: Recruiting Phase 1 study of Myelofibrosis, sponsored by Cellenkos.
NCT05423691 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Cellenkos. The registered enrollment target is 24 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423691, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Cellenkos.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Primary Outcome
* severe (grade 3 or 4) infusion-related toxicity within 24 hours (NCI-CTCAE V5.0) of exposure that does not resolve with standard of care treatment within 72 hours. * regimen related death within 28 days
Conditions Studied
Interventions
- DRUG CK0804
Study Locations (4)
New York
- Columbia University - New York
- Montefiore Einstein Cancer Center - The Bronx
California
- UC Davis Health - Sacramento
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-12-27 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What NCT05423691 shows while recruiting
NCT05423691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which CK0804 is the first listed.
NCT05423691 reports a single indexed study location in New York, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05423691 about?
NCT05423691 is a clinical study titled "Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs". To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
What is the current status of trial NCT05423691?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-12-27. Estimated completion is 2026-12-30.
What conditions does trial NCT05423691 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT05423691?
The interventions under investigation include: CK0804 (DRUG).
Who is sponsoring clinical trial NCT05423691?
This trial is sponsored by Cellenkos, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05423691 being conducted?
This trial has 4 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05423691's enrollment target sits among peer trials
24 49th of 61 higher than 12 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI